Suat Seren Chest Disease and Surgery Training and Research Hospital

İzmir, Turkey

Suat Seren Chest Disease and Surgery Training and Research Hospital

İzmir, Turkey
SEARCH FILTERS
Time filter
Source Type

Ylmaz U.,Suat Seren Chest Disease and Surgery Training and Research Hospital | Yasar Z.,Medistate Kavack Hospital | Korkmaz E.,Suat Seren Chest Disease and Surgery Training and Research Hospital | Yalcn B.,Suat Seren Chest Disease and Surgery Training and Research Hospital | And 2 more authors.
Medicinski Glasnik | Year: 2017

Aim Concurrent chemoradiotherapy (CRT) is the standard of care for locally advanced, unresectable non-small cell lung carcinoma (NSCLC). The aim of this study was to assess the prognostic value of maximum standardized uptake values (SUVmax) in patients with unresectable stage III NSCLC treated with concurrent CRT. Method 18F-FDG PET-CT scans were obtained before and after treatment in patients with unresectable stage III NSCLC treated with concurrent CRT. To determine the prognostic value of SUVmax of the primary tumor (PT), univariate and multivariate Cox regression model were carried out. Results Between January 2008 and December 2013, this study included 43 patients (median age 56 years, 95% male). Univariate analysis showed that having a high post-treatment PT-SUVmax was associated with a higher risk of death and having a high post-treatment PT-SUVmax with a higher risk of disease recurrence. Multivariate analysis showed that having a low post-treatment PT-SUVmax (cut off 3.9) was associated with longer overall and progression free survival (HR 8.55, 95% CI; 2.56-28.55, p=0.000 and HR 2.854, 95% CI; 1.43-5.67, p=0.003, respectively). Conclusion Post-treatment PT-SUVmax may be an independent prognostic factor in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy. © 2017, Medical Association of Zenica-Doboj Canton. All rights reserved.


Kalemci S.,Muǧla University | Micili S.C.,Dokuz Eylül University | Acar T.,Izmir University | Senol T.,OSM Ortadogu Hospital | And 5 more authors.
Clinica Terapeutica | Year: 2013

Background: Thymoquinone (TQ), the main active constituent of the volatile oil extracted from Nigella sativas seeds, is used for the treatment of inflammatory diseases and exhibits a variety of pharma-cological effects. Methods: Twenty-eight BALB/c female mice were divided into four groups: I (sham-operated control group), II, III, and IV. All groups except for the sham-operated group were sensitized and challenged with ovalbumin. The sham-operated group received nebulized saline in challenge period. Mice in groups III and IV were administered TQ at a dose of 3 mg/kg and dexamethasone 1 mg/kg, respectively, intraperito-neally once a day for the final 5 days of the challenge period. Animals were sacrificed 24 h after the last drug administration and the airway samples were evaluated histologically by light microscopy. Results: All histological parameters in Group III, similar to Group IV, were improved when compared to Group II. All variables except numbers of goblet cells were found to be significantly better in Group III and Group IV compared to Group II. Conclusions: In our study, we demonstrated that TQ administration alleviates the pathological changes of chronic asthma. TQ might be a promising therapy for asthma in the future. © Società Editrice Universo (SEU).


Yilmaz U.,Suat Seren Chest Disease and Surgery Training and Research Hospital | Anar C.,Suat Seren Chest Disease and Surgery Training and Research Hospital | Korkmaz E.,Suat Seren Chest Disease and Surgery Training and Research Hospital | Yapicioglu S.,Suat Seren Chest Disease and Surgery Training and Research Hospital | And 2 more authors.
Tumori | Year: 2010

Aims and background. There has been a trend to replace cisplatin with carboplatin in the treatment of small-cell lung carcinoma. The goal of the present study was to determine the efficacy of carboplatin and etoposide followed by thoracic radiotherapy in patients with previously untreated limited disease small-cell lung carcinoma. Methods. From February 2001 to March 2007, 47 patients with limited disease small-cell lung cancer were enrolled in the study. Etoposide, 100mg/m2, was administrated intravenously on days 1-3 in combination with carboplatin, AUC 6, on day 1 every 21 days for 6 cycles. In cases considered to have non-progressive disease following induction chemotherapy, thoracic radiotherapy was given with in a once daily fraction of 2.0 Gy, 5/wk, up to 50-60 Gy. Results. Forty-one patients were evaluated. Median age was 62 (range, 40-78), 88% of patients were male. ECOG PS was 0-1 in 38 patients. Seven of the 41 patients (17.5%) had pleural effusion (one malignant) and 7 patients (17.5%) had involved supraclavicular lymph nodes. Ninety percent of patients had elevated serum lactate dehydrogenase levels. Median follow-up was 13.5 mo. A total of 209 cycles of chemotherapy was administered (median, 6; range, 1-6). Thoracic irradiation was given to 33 patients. The overall response rate to combined modality on an intention-to-treat basis was 73%. Median survival time was 13.7months (95% CI, 10.3-17.1), and median progression-free survival was 9.5 months (95% CI, 8.6-10.4). Two- and four-year overall survival was 23% and 7%, respectively. Grade 3-4 neutropenia and leukopenia were the most common adverse events and occurred in 46.0% and 24.0% of the patients, respectively. Six (14%) patients experienced febrile neutropenia. Three patients (7%) died of sepsis and neutropenic fever. Non-hematological toxicities were mild. Conclusions. Carboplatin and etoposide chemotherapy followed by thoracic radiotherapy in LD-SCLC appears to be unsatisfactory.


Yilmaz U.,Suat Seren Chest Disease and Surgery Training and Research Hospital | Polat G.,Suat Seren Chest Disease and Surgery Training and Research Hospital | Anar C.,Suat Seren Chest Disease and Surgery Training and Research Hospital | Halilcolar H.,Suat Seren Chest Disease and Surgery Training and Research Hospital
Indian Journal of Cancer | Year: 2011

Aims: The aim of this study is to investigate the activity and toxicity of etoposide with AUC 6 doses of carboplatin in patients with previously untreated extensive disease-small-cell lung cancer (SCLC). Materials and Methods: 88 eligible patients were treated with chemotherapy comprised of carboplatin AUC of 6, IV day 1 and etoposide 100 mg/m 2, IV day 1-3. This schedule was repeated every 21 days for maximum of six cycles. Results: Patients characteristics: Median age, 62 years; 84 male; ECOG PS 0-1 in 73 patients, PS 2-3 in 15 patients. A total of 431 cycles were administered (median, 6.0). The complete and partial response rates were 23.9% and 45.5%, respectively. Median overall survival (OS) was 9.0 months (95% confidence interval [CI], 8.09-9.90 m); 84 patients died. The 1-and 2-year survival probabilities were 33.6% and 5.3%, respectively. The median progression-free survival in patients of 65 was 7.2 months (95% CI, 5.81-8.58), 12-month PFS rate was 10%. The median OS was 11.6 months (95% CI, 8.52-14.67 m) and 7.5 months (95% CI, 5.61-9.38 m) in patients with non-liver and liver metastasis, respectively (P = 0.024). The median OS was 9.3 months (95% CI, 7.83-10.76 m) and 7.5 months (95% CI, 5.58-9.44 m) in patients with single and multiple distant metastasis, respectively (P = 0.02). Grade 3-4 neutropenia, thrombocytopenia, and anemia were detected in 57.9%, 15.9%, and 11.4% of patients, respectively. Febrile neutropenia was developed in 12 patients. Conclusion: Etoposide with AUC 6 doses of carboplatin is active and tolerable in patients with extensive disease-SCLC.


PubMed | Suat Seren Chest Disease and Surgery Training and Research Hospital
Type: Journal Article | Journal: Indian journal of cancer | Year: 2012

The aim of this study is to investigate the activity and toxicity of etoposide with AUC 6 doses of carboplatin in patients with previously untreated extensive disease - small-cell lung cancer (SCLC).88 eligible patients were treated with chemotherapy comprised of carboplatin AUC of 6, IV day 1 and etoposide 100 mg/m 2 , IV day 1-3. This schedule was repeated every 21 days for maximum of six cycles.Patients characteristics: Median age, 62 years; 84 male; ECOG PS 0-1 in 73 patients, PS 2-3 in 15 patients. A total of 431 cycles were administered (median, 6.0). The complete and partial response rates were 23.9% and 45.5%, respectively. Median overall survival (OS) was 9.0 months (95% confidence interval [CI], 8.09 - 9.90 m); 84 patients died. The 1- and 2-year survival probabilities were 33.6% and 5.3%, respectively. The median progression-free survival in patients of 65 was 7.2 months (95% CI, 5.81 - 8.58), 12-month PFS rate was 10%. The median OS was 11.6 months (95% CI, 8.52 - 14.67 m) and 7.5 months (95% CI, 5.61 - 9.38 m) in patients with non-liver and liver metastasis, respectively (P = 0.024). The median OS was 9.3 months (95% CI, 7.83 - 10.76 m) and 7.5 months (95% CI, 5.58 - 9.44 m) in patients with single and multiple distant metastasis, respectively (P = 0.02). Grade 3-4 neutropenia, thrombocytopenia, and anemia were detected in 57.9%, 15.9%, and 11.4% of patients, respectively. Febrile neutropenia was developed in 12 patients.Etoposide with AUC 6 doses of carboplatin is active and tolerable in patients with extensive disease - SCLC.

Loading Suat Seren Chest Disease and Surgery Training and Research Hospital collaborators
Loading Suat Seren Chest Disease and Surgery Training and Research Hospital collaborators